Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Karyopharm Reports Third Quarter 2015 Financial Results and Highlights Recent Progress
November 9, 2015 7:30 AM ESTRobust Recruitment and New Study Initiations Continue
Additional Encouraging Data on Selinexor in Combination with Other Active Agents to be Presented at ASH
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2015 and commented on recent accomplishments and clinical development plans for its pipeline of SINE-based therapeutics including selinexor, its lead product candidate.
"This has been a very busy... More
